Market Research Logo

Oral Solid Dosage Pharmaceutical Formulation Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Oral Solid Dosage Pharmaceutical Formulation Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027

Future Market Insights forecasts the global oral solid dosage pharmaceutical formulation market to grow from US$ 493.2 Bn in 2017 to US$ 926.3 Bn by 2027 end. This represents a value CAGR of 6.5% over the forecast period 2017– 2027. Several important factors drive this growth. We present these factors in detail in our report. A snapshot is captured below for our readers’ benefit.

Growth Factor : Most promising yet cost-effective dosage form

Oral solid dosage forms are the most commonly used pharmaceuticals to treat various disease conditions. Oral solid dosage forms are cost-effective and easy to manufacture in comparison with other dosage forms. They offer significant benefits to manufacturers such as trouble free packaging and transportation and increased chemical and physical stability. Oral solids offer many advantages to patients as well. For instance, oral solid dosage forms are often chosen by patients owing to the inherent advantages in dosage administration and no necessity of dose measurement. They can be formulated in different flavours and in different dosage forms in order to increase patient compliance. For instance, few APIs have unpleasant taste, and in order to avoid this, they are manufactured in the form of effervescent tablets to achieve patient acceptability and compliance. Recent advances in drug delivery are enabling oral solid dosage manufacturers to achieve significant bioavailability by adopting novel drug delivery technology platforms. For example, targeted drug delivery and sustained release of dosage forms in oral solid dosage formulations enhance the bioavailability of the drugs and reduce the frequent administration of drugs, thereby contributing to significant growth of oral solid dosage forms.

Growth Factor : Growth in APEJ region driven by rise in affluent consumers and super generics

Huge boost in the APEJ market for oral solid dosage pharmaceutical formulations is coming from a sharp rise in new affluent consumers in countries such as India, China and Korea. Both multinational companies as well as local drug manufacturers are benefiting from the rapidly growing population of India and China. This group of affluent consumers is adopting a wealthy and fast-paced western lifestyle and thus have begun to suffer with western lifestyle related diseases such as diabetes, cancer and obesity, for which they seek and can afford innovative drug treatments. Moreover, generic manufacturers have entered into the production of super-generics i.e., modified versions of approved off-patent small-molecule drugs that offer a therapeutic advantage and thus distinguish them from me-too generic drugs. For instance, Ranbaxy Laboratories Ltd. – India based manufacturer of generic medicine – has developed once-a day Ciprofloxacin tablet, a super generic antibiotic. The company licensed it to Bayer and opened up an opportunity in the global market.

Global Oral Solid Dosage Pharmaceutical Formulation Market Attractiveness Analysis, By Region

North America dominated the global oral solid dosage pharmaceutical formulation market in revenue terms in 2016, and the trend is projected to continue throughout the forecast period. North America is expected to be the most lucrative among all regions, with a market attractiveness index of 2.7. Consolidation of the pharmaceutical industry in the U.S. combined with an expansion in outsourcing is boosting revenue growth of the oral solid dosage pharmaceutical formulation market in the region. APEJ is expected to be the second most lucrative market for oral solid dosage pharmaceuticals, with a market attractiveness index of 2.6. APEJ remains the third largest market due to rapidly increasing penetration of generics in China and India. MEA is expected to remain the least attractive regional market in terms of revenue, with a market attractiveness index of 0.1 over the forecast period. Every market is challenged by certain factors that tend to hamper overall growth. We have focussed on these growth limiters in detail in our report. One such factor restraining market growth is highlighted below.

Diminishing share of oral solids in the development pipeline

Growing research on biologics molecules and their dominance in treating oncology conditions are hampering the growth of the oral solid dosage pharmaceutical formulation market. Furthermore, investments by government organisations to conduct research activities in biologics coupled with an increase in biotech start-ups have had a negative impact on oral solid dosage forms. According to an article published in Contract Pharma, approximately 50% of the pipeline molecules are biologics and the rest in the form of other dosage forms. Companies are betting heavily on biologics owing to their high returns in terms of value. For instance, in 2016, the top 10 drugs generated around US$ 79 Bn in terms of value; among these, 76.8% were from biologics.


1.Executive Summary
1.1. Market Overview
1.2. Market Analysis
1.3. FMI Analysis and Recommendations
1.4. Wheel of Fortune
2.Market Introduction
2.1. Market Taxonomy
2.2. Market Definition
3.Oral Solid Dosage Pharmaceuticals Market View Point
3.1. Macro-Economic Factors
3.2. Opportunity Analysis
4.North America Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
4.1. Introduction
4.2. Regional Market Dynamics
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Trends
4.3. Historical Market Size (US$ Mn) By Country, 2012-2016
4.3.1.U.S.
4.3.2.Canada
4.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
4.4.1.U.S.
4.4.2.Canada
4.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
4.5.1.Tablets
4.5.2.Capsules
4.5.3.Powders
4.5.4.Others
4.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
4.6.1.Tablets
4.6.2.Capsules
4.6.3.Powders
4.6.4.Others
4.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
4.7.1.Immediate Release
4.7.2.Extended Release
4.7.2.1. Sustained Release
4.7.2.2. Controlled Release
4.7.3.Others
4.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
4.8.1.Immediate Release
4.8.2.Extended Release
4.8.2.1. Sustained Release
4.8.2.2. Controlled Release
4.8.3.Others
4.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
4.9.1.Hospital Pharmacy
4.9.2.Retail Pharmacy
4.9.3.Drug Stores
4.9.4.Online Pharmacy
4.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
4.10.1.Hospital Pharmacy
4.10.2.Retail Pharmacy
4.10.3.Drug Stores
4.10.4.Online Pharmacy
4.11. Drivers and Restraints: Impact Analysis
4.12. Market Attractiveness Analysis
4.12.1.By Country
4.12.2.By Dosage Form
4.12.3.By Drug Release Mechanism
4.12.4.By Distribution Channel
4.13. Key Representative Market Participants
4.14. Key Participants Market Presence (Intensity Map)
5.Western Europe Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
5.1. Introduction
5.2. Regional Market Dynamics
5.2.1.Drivers
5.2.2.Restraints
5.2.3.Trends
5.3. Historical Market Size (US$ Mn) By Country, 2012-2016
5.3.1.Germany
5.3.2.U.K
5.3.3.France
5.3.4.Italy
5.3.5.Spain
5.3.6.Rest of Western Europe
5.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
5.4.1.Germany
5.4.2.U.K
5.4.3.France
5.4.4.Italy
5.4.5.Spain
5.4.6.Rest of Western Europe
5.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
5.5.1.Tablets
5.5.2.Capsules
5.5.3.Powders
5.5.4.Others
5.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
5.6.1.Tablets
5.6.2.Capsules
5.6.3.Powders
5.6.4.Others
5.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
5.7.1.Immediate Release
5.7.2.Extended Release
5.7.2.1. Sustained Release
5.7.2.2. Controlled Release
5.7.3.Others
5.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
5.8.1.Immediate Release
5.8.2.Extended Release
5.8.2.1. Sustained Release
5.8.2.2. Controlled Release
5.8.3.Others
5.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
5.9.1.Hospital Pharmacy
5.9.2.Retail Pharmacy
5.9.3.Drug Stores
5.9.4.Online Pharmacy
5.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
5.10.1.Hospital Pharmacy
5.10.2.Retail Pharmacy
5.10.3.Drug Stores
5.10.4.Online Pharmacy
5.11. Drivers and Restraints: Impact Analysis
5.12. Market Attractiveness Analysis
5.12.1.By Country
5.12.2.By Dosage Form
5.12.3.By Drug Release Mechanism
5.12.4.By Distribution Channel
5.13. Key Representative Market Participants
5.14. Key Participants Market Presence (Intensity Map)
6.Eastern Europe Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
6.1. Introduction
6.2. Regional Market Dynamics
6.2.1.Drivers
6.2.2.Restraints
6.2.3.Trends
6.3. Historical Market Size (US$ Mn) By Country, 2012-2016
6.3.1.Russia
6.3.2.Poland
6.3.3.Rest of Eastern Europe
6.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
6.4.1.Russia
6.4.2.Poland
6.4.3.Rest of Eastern Europe
6.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
6.5.1.Tablets
6.5.2.Capsules
6.5.3.Powders
6.5.4.Others
6.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
6.6.1.Tablets
6.6.2.Capsules
6.6.3.Powders
6.6.4.Others
6.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
6.7.1.Immediate Release
6.7.2.Extended Release
6.7.2.1. Sustained Release
6.7.2.2. Controlled Release
6.7.3.Others
6.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
6.8.1.Immediate Release
6.8.2.Extended Release
6.8.2.1. Sustained Release
6.8.2.2. Controlled Release
6.8.3.Others
6.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
6.9.1.Hospital Pharmacy
6.9.2.Retail Pharmacy
6.9.3.Drug Stores
6.9.4.Online Pharmacy
6.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
6.10.1.Hospital Pharmacy
6.10.2.Retail Pharmacy
6.10.3.Drug Stores
6.10.4.Online Pharmacy
6.11. Drivers and Restraints: Impact Analysis
6.12. Market Attractiveness Analysis
6.12.1.By Country
6.12.2.By Dosage Form
6.12.3.By Drug Release Mechanism
6.12.4.By Distribution Channel
6.13. Key Representative Market Participants
6.14. Key Participants Market Presence (Intensity Map)
7.Latin America Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
7.1. Introduction
7.2. Regional Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Trends
7.3. Historical Market Size (US$ Mn) By Country, 2012-2016
7.3.1.Brazil
7.3.2.Mexico
7.3.3.Rest of Latin America
7.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
7.4.1.Brazil
7.4.2.Mexico
7.4.3.Rest of Latin America
7.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
7.5.1.Tablets
7.5.2.Capsules
7.5.3.Powders
7.5.4.Others
7.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
7.6.1.Tablets
7.6.2.Capsules
7.6.3.Powders
7.6.4.Others
7.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
7.7.1.Immediate Release
7.7.2.Extended Release
7.7.2.1. Sustained Release
7.7.2.2. Controlled Release
7.7.3.Others
7.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
7.8.1.Immediate Release
7.8.2.Extended Release
7.8.2.1. Sustained Release
7.8.2.2. Controlled Release
7.8.3.Others
7.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
7.9.1.Hospital Pharmacy
7.9.2.Retail Pharmacy
7.9.3.Drug Stores
7.9.4.Online Pharmacy
7.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
7.10.1.Hospital Pharmacy
7.10.2.Retail Pharmacy
7.10.3.Drug Stores
7.10.4.Online Pharmacy
7.11. Drivers and Restraints: Impact Analysis
7.12. Market Attractiveness Analysis
7.12.1.By Country
7.12.2.By Dosage Form
7.12.3.By Drug Release Mechanism
7.12.4.By Distribution Channel
7.13. Key Representative Market Participants
7.14. Key Participants Market Presence (Intensity Map)
8.Asia Pacific Excluding Japan Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
8.1. Introduction
8.2. Regional Market Dynamics
8.2.1.Drivers
8.2.2.Restraints
8.2.3.Trends
8.3. Historical Market Size (US$ Mn) By Country, 2012-2016
8.3.1.China
8.3.2.India
8.3.3.Australia and New Zealand
8.3.4.ASEAN
8.3.5.Rest of APEJ
8.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
8.4.1.China
8.4.2.India
8.4.3.Australia and New Zealand
8.4.4.ASEAN
8.4.5.Rest of APEJ
8.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
8.5.1.Tablets
8.5.2.Capsules
8.5.3.Powders
8.5.4.Others
8.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
8.6.1.Tablets
8.6.2.Capsules
8.6.3.Powders
8.6.4.Others
8.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
8.7.1.Immediate Release
8.7.2.Extended Release
8.7.2.1. Sustained Release
8.7.2.2. Controlled Release
8.7.3.Others
8.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
8.8.1.Immediate Release
8.8.2.Extended Release
8.8.2.1. Sustained Release
8.8.2.2. Controlled Release
8.8.3.Others
8.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
8.9.1.Hospital Pharmacy
8.9.2.Retail Pharmacy
8.9.3.Drug Stores
8.9.4.Online Pharmacy
8.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
8.10.1.Hospital Pharmacy
8.10.2.Retail Pharmacy
8.10.3.Drug Stores
8.10.4.Online Pharmacy
8.11. Drivers and Restraints: Impact Analysis
8.12. Market Attractiveness Analysis
8.12.1.By Country
8.12.2.By Dosage Form
8.12.3.By Drug Release Mechanism
8.12.4.By Distribution Channel
8.13. Key Representative Market Participants
8.14. Key Participants Market Presence (Intensity Map)
9.Japan Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
9.1. Introduction
9.2. Regional Market Dynamics
9.2.1.Drivers
9.2.2.Restraints
9.2.3.Trends
9.3. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
9.3.1.Tablets
9.3.2.Capsules
9.3.3.Powders
9.3.4.Others
9.4. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
9.4.1.Tablets
9.4.2.Capsules
9.4.3.Powders
9.4.4.Others
9.5. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
9.5.1.Immediate Release
9.5.2.Extended Release
9.5.2.1. Sustained Release
9.5.2.2. Controlled Release
9.5.3.Others
9.6. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
9.6.1.Immediate Release
9.6.2.Extended Release
9.6.2.1. Sustained Release
9.6.2.2. Controlled Release
9.6.3.Others
9.7. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
9.7.1.Hospital Pharmacy
9.7.2.Retail Pharmacy
9.7.3.Drug Stores
9.7.4.Online Pharmacy
9.8. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
9.8.1.Hospital Pharmacy
9.8.2.Retail Pharmacy
9.8.3.Drug Stores
9.8.4.Online Pharmacy
9.9. Drivers and Restraints: Impact Analysis
9.10. Market Attractiveness Analysis
9.10.1.By Dosage Form
9.10.2.By Drug Release Mechanism
9.10.3.By Distribution Channel
9.11. Key Representative Market Participants
9.12. Key Participants Market Presence (Intensity Map)
10. Middle East and Africa Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
10.1. Introduction
10.2. Regional Market Dynamics
10.2.1.Drivers
10.2.2.Restraints
10.2.3.Trends
10.3. Historical Market Size (US$ Mn) By Country, 2012-2016
10.3.1.GCC Countries
10.3.2.South Africa
10.3.3.Rest of Middle East and Africa
10.4. Market Size (US$ Mn) Forecast By Country, 2017-2027
10.4.1.GCC Countries
10.4.2.South Africa
10.4.3.Rest of Middle East and Africa
10.5. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
10.5.1.Tablets
10.5.2.Capsules
10.5.3.Powders
10.5.4.Others
10.6. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
10.6.1.Tablets
10.6.2.Capsules
10.6.3.Powders
10.6.4.Others
10.7. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
10.7.1.Immediate Release
10.7.2.Extended Release
10.7.2.1.Sustained Release
10.7.2.2.Controlled Release
10.7.3.Others
10.8. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
10.8.1.Immediate Release
10.8.2.Extended Release
10.8.2.1.Sustained Release
10.8.2.2.Controlled Release
10.8.3.Others
10.9. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
10.9.1.Hospital Pharmacy
10.9.2.Retail Pharmacy
10.9.3.Drug Stores
10.9.4.Online Pharmacy
10.10. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
10.10.1.Hospital Pharmacy
10.10.2.Retail Pharmacy
10.10.3.Drug Stores
10.10.4.Online Pharmacy
10.11. Drivers and Restraints: Impact Analysis
10.12. Market Attractiveness Analysis
10.12.1.By Country
10.12.2.By Dosage Form
10.12.3.By Drug Release Mechanism
10.12.4.By Distribution Channel
10.13. Key Representative Market Participants
10.14. Key Participants Market Presence (Intensity Map)
11. Forecast Factors: Relevance and Impact
12. Forecast Assumptions
13. Competition Landscape
13.1. Market Structure
13.2. Competition Intensity Mapping By Market Taxonomy
13.3. Competition Dashboard
13.4. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
13.4.1.AstraZeneca Plc.
13.4.2.Bristol-Myers Squibb Company
13.4.3.Eli Lilly and Company
13.4.4.Gilead Sciences
13.4.5.Merck & Co. Inc.
13.4.6.Novartis AG
13.4.7.Pfizer Inc.
13.4.8.AbbVie Inc.
13.4.9. Boehringer Ingelheim GmbH
13.4.10.Hoffman-La-Roche Ltd.
13.4.11. Johnson & Johnson
13.4.12. Biogen Inc.
13.4..13. Bayer AG
13.5.14. Teva Pharmaceticals
13.5.15. Amgen Inc.
13.5.16. Takeda Pharmaceutical Company Ltd.
13.5.17. Otsuka Pharmaceutical Co., Ltd.
13.5.18. Shire Plc.
13.5.19. Celgene Corporation
13.5.20. Astellas Pharma Inc.
14. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027 By Region
14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) By Region
14.2.1.North America
14.2.2.Western Europe
14.2.3.Eastern Europe
14.2.4.Latin America
14.2.5.Asia Pacific Excluding Japan
14.2.6.Japan
14.2.7.Middle East and Africa
14.3. Market Size (US$ Mn) Forecast By Region
14.3.1.North America
14.3.2.Western Europe
14.3.3.Eastern Europe
14.3.4.Latin America
14.3.5.Asia Pacific Excluding Japan
14.3.6.Japan
14.3.7.Middle East and Africa
14.4. Market Attractiveness Analysis By Region
15. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Dosage Form
15.1. Introduction/Key Finding
15.2. Historical Market Size (US$ Mn) By Dosage Form, 2012-2016
15.2.1.Tablets
15.2.2.Capsules
15.2.3.Powders
15.2.4.Others
15.3. Market Size (US$ Mn) Forecast By Dosage Form Type, 2017-2027
15.3.1.Tablets
15.3.2.Capsules
15.3.3.Powders
15.3.4.Others
15.4. Key Trends / Developments
15.5. Drivers and Restraints: Impact Analysis
15.6. Market Attractiveness Analysis By Dosage Form Type
16. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Drug Release Mechanism
16.1.Introduction/Key Finding
16.2. Historical Market Size (US$ Mn) By Drug Release Mechanism, 2012-2016
16.2.1.Immediate Release
16.2.2.Extended Release
16.2.2.1.Sustained Release
16.2.2.2.Controlled Release
16.2.3.Others
16.3. Market Size (US$ Mn) Forecast By Drug Release Mechanism, 2017-2017
16.3.1.Immediate Release
16.3.2.Extended Release
16.3.2.1.Sustained Release
16.3.2.2.Controlled Release
16.3.3.Others
16.4. Key Trends / Developments
16.5. Drivers and Restraints: Impact Analysis
16.6.Market Attractiveness Analysis By Drug Release Mechanism
17. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027, By Distribution Channel
17.1. Introduction/Key Finding
17.2. Historical Market Size (US$ Mn) By Distribution Channel, 2012-2016
17.2.1.Hospital Pharmacy
17.2.2.Retail Pharmacy
17.2.3.Drug Stores
17.2.4.Online Pharmacy
17.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2017-2027
17.3.1.Hospital Pharmacy
17.3.2.Retail Pharmacy
17.3.3.Drug Stores
17.3.4.Online Pharmacy
17.4. Drivers and Restraints: Impact Analysis
17.5. Market Attractiveness Analysis By Distribution Channel
18. Global Oral Solid Dosage Pharmaceuticals Market Analysis 2012–2016 and Forecast 2017–2027
18.1. Market Size and Y-o-Y Growth
18.2. Absolute $ Opportunity
18.3. Value Chain

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report